MA31323B1 - Agents therapeutiques - Google Patents

Agents therapeutiques

Info

Publication number
MA31323B1
MA31323B1 MA32295A MA32295A MA31323B1 MA 31323 B1 MA31323 B1 MA 31323B1 MA 32295 A MA32295 A MA 32295A MA 32295 A MA32295 A MA 32295A MA 31323 B1 MA31323 B1 MA 31323B1
Authority
MA
Morocco
Prior art keywords
therapeutic agents
ht2a
neurotransmission
dysfunctional
serotonin
Prior art date
Application number
MA32295A
Other languages
Arabic (ar)
English (en)
Inventor
Mark T Bilodeau
Kausik K Nanda
B Wesley Trotter
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39540659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31323(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA31323B1 publication Critical patent/MA31323B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des agents thérapeutiques représentés par la formule (i) qui sont des antipsychotiques atypiques et qui sont utiles dans le traitement de troubles neurologiques et psychiatriques associés à un disfonctionnement de la neurotransmission de la dopamine d2 et de la sérotonine 5-ht2a. Dans laquelle; r1 est un alkyle en c1-c6, qui est non substitué ou substitué par 1-6 fluoro, r1 et le groupe hydroxyle sur le cycle étant fixés au même atome de carbone; ou un sel pharmaceutiquement acceptable de ces composés.
MA32295A 2007-04-04 2009-10-21 Agents therapeutiques MA31323B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92175907P 2007-04-04 2007-04-04
PCT/US2008/004336 WO2008124030A1 (fr) 2007-04-04 2008-04-03 Agents thérapeutiques

Publications (1)

Publication Number Publication Date
MA31323B1 true MA31323B1 (fr) 2010-04-01

Family

ID=39540659

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32295A MA31323B1 (fr) 2007-04-04 2009-10-21 Agents therapeutiques

Country Status (32)

Country Link
US (3) US8252799B2 (fr)
EP (1) EP2144905B1 (fr)
JP (2) JP5097265B2 (fr)
KR (1) KR101562835B1 (fr)
CN (1) CN101675046B (fr)
AU (1) AU2008236705B2 (fr)
BR (1) BRPI0809492A2 (fr)
CA (1) CA2682494C (fr)
CO (1) CO6300938A2 (fr)
CR (1) CR11047A (fr)
CY (1) CY1113649T1 (fr)
DK (1) DK2144905T3 (fr)
DO (1) DOP2009000232A (fr)
EC (1) ECSP099674A (fr)
ES (1) ES2398312T3 (fr)
GT (1) GT200900258A (fr)
HR (1) HRP20130041T8 (fr)
IL (1) IL201235A (fr)
MA (1) MA31323B1 (fr)
MX (1) MX2009010678A (fr)
MY (1) MY153868A (fr)
NI (1) NI200900175A (fr)
NZ (1) NZ580167A (fr)
PL (1) PL2144905T3 (fr)
PT (1) PT2144905E (fr)
RS (1) RS52661B (fr)
RU (1) RU2468025C2 (fr)
SI (1) SI2144905T1 (fr)
SV (1) SV2009003380A (fr)
UA (1) UA96015C2 (fr)
WO (1) WO2008124030A1 (fr)
ZA (1) ZA200906525B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000032987A (ja) * 1998-07-16 2000-02-02 Dai Ichi Seiyaku Co Ltd Ｄｎａ
ES2685780T3 (es) 2002-08-22 2018-10-11 Sumitomo Dainippon Pharma Co., Ltd. Agente para el tratamiento de esquizofrenia
CN1826338B (zh) 2003-06-23 2011-07-13 大日本住友制药株式会社 老年性痴呆症治疗药
WO2005080976A1 (fr) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Procédé de recherche par criblage in vivo d'un agent thérapeutique pour un dysfonctionnement de la mémoire/de l'apprentissage par schizophrénie
AU2008236705B2 (en) 2007-04-04 2014-01-23 Merck Sharp & Dohme Corp. Therapeutic agents
US20110124659A1 (en) * 2009-11-17 2011-05-26 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142205A1 (fr) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant de l'alcool benzylique
WO2013142198A1 (fr) * 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters d'acides gras
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
EP3718536A1 (fr) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Compositions pharmaceutiques présentant une stabilité améliorée au stockage
CN103207246B (zh) * 2012-12-21 2017-10-10 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法
CN104140421B (zh) * 2013-05-08 2017-04-05 上海医药工业研究院 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用
EP3119399A4 (fr) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
CA3208241A1 (fr) * 2015-08-31 2017-03-09 Nutramax Laboratories, Inc. Compositions comprenant du magnolia, du phellodendron, de la theanine et/ou une proteine du petit-lait
CA3092335A1 (fr) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Strategie de dosage d'aripiprazole
WO2024091523A1 (fr) * 2022-10-24 2024-05-02 2A Biosciences, Inc. Analogues de phényléthylamine à conformation restreinte

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
US5219879A (en) * 1990-03-05 1993-06-15 Du Pont Merck Pharmaceutical Company Heterocyclic steroid compounds
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
IT1242929B (it) * 1990-11-07 1994-05-18 Nordica Spa Struttura di leva per calzature sportive, particolarmente per scarponi da sci
WO1996014297A1 (fr) * 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de lactame
JP3775823B2 (ja) 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
CA2394548A1 (fr) * 1999-12-17 2001-06-21 Joseph P. Yevich Composes heterocycliques antipsychotiques
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
CN1826338B (zh) 2003-06-23 2011-07-13 大日本住友制药株式会社 老年性痴呆症治疗药
JP4610485B2 (ja) 2003-07-29 2011-01-12 大日本住友製薬株式会社 イミド化合物の製造方法
WO2005080976A1 (fr) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Procédé de recherche par criblage in vivo d'un agent thérapeutique pour un dysfonctionnement de la mémoire/de l'apprentissage par schizophrénie
AU2008236705B2 (en) 2007-04-04 2014-01-23 Merck Sharp & Dohme Corp. Therapeutic agents
US20090076027A1 (en) 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20110003994A1 (en) 2009-07-02 2011-01-06 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative

Also Published As

Publication number Publication date
US20120316181A1 (en) 2012-12-13
DK2144905T3 (da) 2013-03-11
RS52661B (sr) 2013-06-28
CA2682494C (fr) 2011-10-11
SI2144905T1 (sl) 2013-03-29
CN101675046A (zh) 2010-03-17
JP2010523567A (ja) 2010-07-15
US8252799B2 (en) 2012-08-28
HRP20130041T1 (hr) 2013-02-28
PT2144905E (pt) 2013-02-26
JP2013028626A (ja) 2013-02-07
ZA200906525B (en) 2010-04-28
MX2009010678A (es) 2009-10-23
CY1113649T1 (el) 2016-10-05
CN101675046B (zh) 2013-02-06
ECSP099674A (es) 2009-11-30
PL2144905T3 (pl) 2013-04-30
MY153868A (en) 2015-03-30
US8410111B2 (en) 2013-04-02
GT200900258A (es) 2011-10-18
RU2009136592A (ru) 2011-04-20
HK1134291A1 (en) 2010-04-23
US20130178481A1 (en) 2013-07-11
KR20090127416A (ko) 2009-12-11
IL201235A (en) 2013-12-31
NI200900175A (es) 2010-09-07
SV2009003380A (es) 2010-04-13
AU2008236705B2 (en) 2014-01-23
KR101562835B1 (ko) 2015-10-23
DOP2009000232A (es) 2016-11-15
EP2144905A1 (fr) 2010-01-20
EP2144905B1 (fr) 2012-11-28
IL201235A0 (en) 2010-05-31
JP5686780B2 (ja) 2015-03-18
AU2008236705A1 (en) 2008-10-16
CA2682494A1 (fr) 2008-10-16
NZ580167A (en) 2012-02-24
UA96015C2 (en) 2011-09-26
CR11047A (es) 2009-10-23
WO2008124030A1 (fr) 2008-10-16
JP5097265B2 (ja) 2012-12-12
ES2398312T3 (es) 2013-03-15
BRPI0809492A2 (pt) 2014-09-23
US9867821B2 (en) 2018-01-16
HRP20130041T8 (en) 2013-03-31
US20100105697A1 (en) 2010-04-29
CO6300938A2 (es) 2011-07-21
RU2468025C2 (ru) 2012-11-27

Similar Documents

Publication Publication Date Title
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA30228B1 (fr) Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4
UA96015C2 (en) Therapeutic agents
MA32231B1 (fr) Composés organiques
AR067538A1 (es) Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa
MA32171B1 (fr) Compose heterocyclique
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA34450B1 (fr) Dérivés de l'imidazopyridine, procédé pour leur préparation, et leur utilisation thérapeutique
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
UA95454C2 (uk) Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
MA31373B1 (fr) Composes amino-heterocycliques
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
EA200500006A1 (ru) Лекарственное средство для лечения нейродегенеративных заболеваний
MA31742B1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
MA28422B1 (fr) Derives de n- (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1
MA38217A1 (fr) Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2
MA35133B1 (fr) Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5
WO2008105408A1 (fr) Nouveau dérivé de pyrrole ayant un groupe uréide et un groupe aminocarbonyle comme substituants
TN2011000550A1 (fr) Derives de cyclopenta[c] pyrrolyla lkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
MEP11508A (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
MA41790B1 (fr) Dérivé de morphinane
MA31738B1 (fr) Triazolo {1,5-a}quinoléines utilises comme ligands du recepteur a3 de l'adenosine
MA38885A1 (fr) Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
EA201071296A1 (ru) Агонист глюкокортикоидного рецептора, включающий 2,2,4-триметил-6-фенил-1,2-дигидрохинолиновые производные, содержащие замещенную оксигруппу